Skip to content

Open labelled, single arm, interventional study of topical dutasteride lotion for androgenetic alopecia.

Assessment of efficacy of topical dutasteride lotion in the treatment of androgenetic alopecia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041637
Enrollment
10
Registered
2022-04-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Topical dutasteride lotion: Topical dutasteride lotion on the scalp twice daily for 12 weeks, subject aged 18-60 years. Control Intervention1: NA: NA

Sponsors

CUTIS Academy of Cutaneous Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients aged 18 - 60 years diagnosed with mild to moderate androgenetic alopecia attending the OPD (Norwood Hamilton scale III to V and Ludwig scale II and III) 2.Patients willing to refrain from other forms of treatment including other topical medications, oral medications for hair loss (other than the nutritional supplement prescribed), laser treatments, injectable treatments and hair transplantation for the duration of the study. 3.Women of child-bearing age with FPHL, who are not planning pregnancy in the next 2 years and are willing to give consent stating the same. 4.Patients who are willing to appear for regular follow ups and follow the prescribed treatment regularly.

Exclusion criteria

Exclusion criteria: 1.Patients suffering from other causes of non-cicatricial alopecia or cicatricial alopecia. 2.Patients suffering from infectious, auto-immune, or other disorders affecting skin of scalp. 3.Patients already on drugs that would affect the hair cycle in past 3 months. 4.Patients suffering from severe AGA (Norwood Hamilton scale VI to VII). 5. Women of child-bearing age planning pregnancy in the next 2 years. 6.Patients known to be allergic to any of the components of the study medications. 7.Patients with known malignancy or those on chemotherapy. 8.Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
To know the efficacy of topical dutasteride lotion in the treatment of androgenetic alopecia. Parameters assessed - Increase in Hair density and Increase in Terminal: Vellus hair ratio Assessment of global photographs and Trichoscopy images will be doneTimepoint: After 3 months

Secondary

MeasureTime frame
Clinical photographs â?? taken in same position and with uniform illumination. Grading of Hair loss â?? Norwood Hamilton, Ludwigâ??s grading. Trichoscopy with video-dermoscope (Fotofinder) before and at the end of study period (Day 0 and Day 90) to analyse the outcome.Timepoint: After 3 months

Countries

India

Contacts

Public ContactDr Megha C

CUTIS Academy of Cutaneous Sciences

mghzoots@gmail.com8095196167

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026